Semaglutide for weight loss in people with obesity as an adjunctive treatment for hidradenitis suppurativa: its impact on disease control and quality of life

Abstract

Hidradenitis suppurativa (HS) has a significant impact on patients’ quality of life (QoL) and mortality. We report the use of semaglutide and its impact on disease control and QoL in 30 patients with obesity attending an HS specialty clinic. These retrospective data suggest that the addition of semaglutide to standard HS treatments results in improvement in QoL and fewer HS flares. The retrospective nature of the study is a limitation. Placebo-controlled randomized clinical trials should be done in HS to assess the efficacy of semaglutide in this debilitating condition.